|
Hemato-oncology
The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study
Jin-Hyuk Choi, Yong Won Choi, Hyun Woo Lee, Seok Yun Kang, Geum Sook Jeong, Mi Sun Ahn, Young-Taek Oh, O kyu Noh, Se-Hyuk Kim, Tae Hoon Roh, Seung Soo Sheen
Korean J Intern Med. 2022;37(2):434-443. Published online February 16, 2022
Background/Aims: The optimal treatment (Tx) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) remains to be determined.
Methods: A retrospective review was conducted on 77 NSCLC patients with synchronous BM who underwent first-..
|
|
|
Pulmonology
Clinical efficacy of adjuvant chemotherapy in stage IB (< 4 cm) non-small cell lung cancer patients with high-risk factors
Juwhan Choi, Jee Youn Oh, Young Seok Lee, Kyung Hoon Min, Jae Jeong Shim, Sue In Choi, Dong Won Park, Chan Kwon Park, Eun Joo Kang, Hwan Seok Yong, Bong Kyung Shin, Hyun Koo Kim, Sung Yong Lee
Korean J Intern Med. 2022;37(1):127-136. Published online July 29, 2021
Background/Aims: Adjuvant chemotherapy is the standard of care for resected stage II-IIIA non-small cell lung cancer (NCSLC). The efficacy of adjuvant chemotherapy in stage IB (< 4 cm) NSCLC with high-risk factors is controversial.
Methods: This retrospective multicenter study included 285 stage IB..
|
|
|
Hemato-oncology
Prognostic role of beclin-1 in locally advanced non-small cell lung cancer in patients receiving docetaxel-platinum induction chemotherapy
Hee Yeon Lee, Jung Ha Shin, Kyo-Young Lee, Jae Kil Park, Sook Whan Sung, Yeon Sil Kim, Jin-Hyoung Kang, Jeong-Oh Kim
Korean J Intern Med. 2019;34(2):401-408. Published online September 6, 2018
Background/Aims: The outcome of local treatment for advanced non-small cell lung cancer (NSCLC) remains poor, with therapies such as induction chemotherapy (IC) yielding conflicting results. This study aimed to assess the clinicopathologic and prognostic significance of the excision repair cross-com..
|
|
|
Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer
Sung Won Lim, Myung-Ju Ahn
Korean J Intern Med. 2019;34(1):50-59. Published online September 3, 2018
Lung cancer remains a leading cause of cancer mortality worldwide, including in Korea. Systemic therapy including platinum-based chemotherapy and targeted therapy should be provided to patients with stage IV non-small cell lung cancer (NSCLC). Applications of targeted therapy, such as an epidermal g..
|
|
|
Invasive pulmonary aspergillosis in a patient with metastatic non-small cell lung cancer after
treatment with gefitinib
Sejeong Park, Soyoung Park, Hana Choi, Ji Young Park, Hyo Seok Lim, Myung Jae Park, Si-Young Kim
Korean J Intern Med. 2018;33(1):211-213. Published online November 25, 2016
|
|
|
Hemato-oncology
Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer
Min Young Baek, Hee Kyung Ahn, Kyu Ree Park, Hwa-Sun Park, Shin Myung Kang, Inkeun Park, Young Saing Kim, Junshik Hong, Sun Jin Sym, Jinny Park, Jae Hoon Lee, Dong Bok Shin, Eun Kyung Cho
Korean J Intern Med. 2018;33(1):168-175. Published online April 20, 2016
Background/Aims: We investigated the time taken for patients with metastatic non-small cell lung cancer (NSCLC) to develop brain metastases (BM), as well as their subsequent overall median survival following diagnosis, considering the epidermal growth factor receptor (EGFR) mutational status...
|
|
|
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
Sehhoon Park, Ji-Yeon Kim, Se-Hoon Lee, Beomseok Suh, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
Korean J Intern Med. 2017;32(3):514-522. Published online April 14, 2017
Background/Aims: The predictive and prognostic value of KRAS mutation and its type of mutations in non-small cell lung cancer (NSCLC) are controversial. This clinical study was designed to investigate the predictive value of KRAS mutations and its mutation types to pemetrexed and gemcitabine based t..
|
|
|
Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
Yong Won Choi, Jin-Hyuk Choi
Korean J Intern Med. 2017;32(3):422-428. Published online March 30, 2017
An exon 19 deletion and a L858R mutation in exon 21 of the epidermal growth factor receptor (EGFR) are the two most common mutations that predict favorable efficacy of EGFR tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). Many retrospective and prospective studi..
|
|
|
Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small
cell lung cancer with activating epidermal growth factor receptor mutations
Sehhoon Park, Seongyeol Park, Se-Hoon Lee, Beomseok Suh, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Young Whan Kim, Dae Seog Heo
Korean J Intern Med. 2016;31(6):1140-1149. Published online March 28, 2016
Background/Aims: Pretreatment nutritional status is an important prognostic factor in patients treated with conventional cytotoxic chemotherapy. In the era of target therapies, its value is overlooked and has not been investigated. The aim of our study is to evaluate the value of nutritional status ..
|
|
|
Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
Kyoung Min Cho, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Dae Seog Heo
Korean J Intern Med. 2015;30(6):891-898. Published online October 30, 2015
Background/Aims: The purpose of this study was to identify predictive factors for erlotinib treatment in non-small cell lung cancer (NSCLC) patients following gefitinib failure.
Methods: Forty-five patients with NSCLC who were treated with erlotinib following gefitinib failure at Seoul National Uni..
|
|
|
Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
Yoon Ho Ko, Myung Ah Lee, Yeong Seon Hong, Kyung Shik Lee, Hyun Jin Park, Ie Ryung Yoo, Yeon Sil Kim, Young Kyoon Kim, Keon Hyun Jo, Young Pil Wang, Kyo Young Lee, Jin Hyoung Kang
Korean J Intern Med. 2007;22(3):178-185. Published online September 30, 2007
BackgroundSecond-line chemotherapy offers advanced non-small cell lung cancer (NSCLC) patients a small, but significant increase in survival. Docetaxel is usually administered as a 3-week schedule, yet there is significant toxicity with this therapy. Therefore, a weekly schedu..
|
|
|
